Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope spike. One such antibody, PGT135, contacts the intrinsic mannose patch of gp120 at the Asn332, Asn392, and Asn386 glycosylation sites. Here, site-specific glycosylation analysis of recombinant gp120 revealed glycan microheterogeneity sufficient to explain the existence of a minor population of virions resistant to PGT135 neutralization. Target microheterogeneity and antibody glycan specificity are therefore important parameters in HIV-1 vaccine design.
T
he isolation of potent, broadly neutralizing antibodies (bnAbs) from infected HIV-1 individuals has focused efforts toward the molecular characterization of their epitopes (1) (2) (3) (4) (5) . These antibodies have potential value in a therapeutic context, and their epitopes represent key vaccine leads (6-12). Structural and biochemical studies have revealed that a number of the recently isolated bnAbs penetrate the heavily glycosylated surface of the HIV-1 envelope spike, making contacts with both the glycans and the protein underneath (1-3, 13-22) Characterization of the glycan-containing epitopes has revealed that much of the glycan shield is vulnerable to antibody recognition (5). Many glycans within the outer domain of gp120 are protected from normal glycan processing and do not form complex-type glycans, instead remaining as immature oligomannose-type glycans. This region is known as the "intrinsic mannose patch" since it contains oligomannose-type glycans, regardless of whether presented in the context of isolated gp120 monomers or functional virions (23) (24) (25) .
The intrinsic mannose patch is targeted by the so-called "mannose patch-dependent" antibodies, which include PGT121 to -124, 10-1074, PGT125 to -128, PGT130 and -131, PGT135 to -137, and 2G12 (14) (15) (16) (26) (27) (28) (29) . These antibodies display remarkable potencies against a diverse panel of HIV-1 strains, although their breadth varies both between and within families (2, 30). PGT135 was found to neutralize 33% of viruses from a 162-crossclade-pseudovirus panel. This neutralization is equivalent to the breadth of b12, which has a protein-based epitope at the CD4 binding site, but is lower than those of other Asn332-dependent bnAbs, such as PGT128 and PGT121, which neutralized 72% and 70% of the panel, respectively (2). This lower breadth of neutralization has been attributed to the limited prevalence of the larger number of critical contact residues (Asn332, Asn392, and His330) across different isolates (15) compared to PGT121 and PGT128. In addition to these properties, inspection of neutralization profiles reveals that, despite containing the required target residues, for some strains of HIV-1, neutralization is incomplete, with plateaus that do not reach 100% (15) . A crystal structure of a PGT135 Fab domain in complex with the gp120 core revealed that the majority of the interactions were mediated through contact with the glycans at the Asn332, Asn392, and Asn386 sites, with 1,010 Å 2 and 438 Å 2 of buried surface area contacting gp120 glycans and protein, respectively (15) . Given the extensive contribution of glycans to the binding interaction, we hypothesized that the incomplete neutralization of some isolates by PGT135 could partially derive from microheterogeneity at the target glycan sites, whereby the presence of certain glycoforms precludes the binding of PGT135.
To investigate this, we performed site-specific glycosylation analysis of the glycan sites targeted by PGT135, as observed in the crystal structure (15): Asn332, Asn386, and Asn392 (Fig. 1) . The BaL isolate was chosen as this has been demonstrated to exhibit some resistance to neutralization by PGT135, with only about 80% of wild-type virus neutralized (15) . Recombinant monomeric gp120 BaL was expressed in HEK 293T cells and purified by immobilized metal affinity chromatography followed by size exclusion chromatography. We previously observed that recombinant gp120 expressed in this way reproduces the intrinsic population of the oligomannose-type glycans present on virus produced in peripheral blood mononuclear cells (PBMCs), providing a good model for analyzing this component of Env glycosylation (24, 25) . Glycopeptides containing a target glycan site were generated by in-solution protease digestions of reduced and alkylated gp120 BaL and isolated by reverse-phase high-performance liquid chromatography (RP-HPLC).
Asn332-containing glycopeptides (sequence QAHCN 332 LSR) were isolated in a fraction from a tryptic digest, performed according to the manufacturer's instructions (Promega), and were analyzed by matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) ( Fig. 2A) . This revealed the glycoforms at the Asn332 site to be overwhelmingly dominated by Man 8 GlcNAc 2 and Man 9 GlcNAc 2 glycans, with trace levels of Man 5-7 GlcNAc 2 ( Table 1) . Confirmation of the glycopeptide identity was performed by tandem MS (MS/MS) fragmentation (Fig. 2B ). Since the ionization of molecules can be influenced by their chemical composition, the measured abundances were validated by quantitating the glycans directly. This was achieved by PNGase F digestion of the glycopeptide fractions to release the glycans, which were then labeled with 2-aminobenzamide (2-AB) and analyzed by hydrophilic interaction liquid chromatographyultraperformance liquid chromatography (HILIC-UPLC) (Fig.  2C) . Comparison of the MALDI-MS glycopeptide spectrum and the HILIC-UPLC glycan profile revealed a very high degree of similarity, validating the use of MALDI-MS for the analysis of glycopeptides containing only oligomannose-type glycans.
In the crystal structure, PGT135 contacts an area of 365 Å 2 across the Asn332 glycan of gp120, with a further 547 Å 2 of contacts with Asn392 and a minor contribution of 99 Å 2 from Asn386 (15). The Asn392 and Asn386 sites were not resolvable using a tryptic digestion; instead chymotrypsin (Promega) was used to produce N 392 STW and YCN 386 STQLF glycopeptides (Fig. 3 ). These glycosylation sites displayed different patterns of microheterogeneity to the Asn332 site ( Table 1 ). The Asn392 site was primarily populated by Man 8 GlcNAc 2 glycans (62%), with lower levels of Man 5 GlcNAc 2 and Man 9 GlcNAc 2 and trace amounts of Man 4 GlcNAc 2 , Man 6 GlcNAc 2 , and Man 7 GlcNAc 2 ( Fig. 3A ; Table  1 ). Meanwhile the Asn386 site displayed a more even distribution of oligomannose-type glycans, with Man 7 GlcNAc 2 and Man 8 GlcNAc 2 predominating ( Fig. 3C ; Table 1 ).
The oligomannose-type nature of the glycans at the Asn332, Asn392, and Asn386 sites is consistent with their location on the densely glycosylated outer domain: the crowded environment helps restrict access by glycosidases and glycosyltransferases, which would otherwise lead to the formation of an array of complex-and hybrid-type glycan structures, as observed at more peripheral glycan sites (24, (31) (32) (33) . However, despite the more restricted microheterogeneity at these sites, there remains a distribution of the individual oligomannose-type glycans, which may affect the capacity for PGT135 binding given its glycan specificity. Glycan array data revealed a preference for large oligomannosetype glycans (Man 7-9 GlcNAc 2 ) (15) . Such a preference, at least at the Asn392 site, can be rationalized by the extensive interactions of PGT135 along the full length of the D1 arm of a Man 8 GlcNAc 2 glycan present in the crystal structure (15) . While the population of smaller oligomannose glycans at the Asn392 site might not capitalize on all possible binding interactions with PGT135, their presence does not necessarily preclude binding. However, the plateau in neutralization observed by us (Fig. 4A ) and others (15) at around 80 to 85% for BaL pseudovirus suggests there's a population of virus that cannot be bound effectively. Modeling of a Man 9 GlcNAc 2 glycan at the Asn392 site revealed that the presence of a terminal D2 mannose residue would induce a steric clash with the complementarity determining region (CDR) H3 loop of PGT135 (15) .
To assess the compatibility of Man 9 GlcNAc 2 glycans with PGT135 binding, we expressed gp120 in the presence of kifunensine, which produced a glycan profile containing over 90% Man 9 GlcNAc 2 (Fig. 4B) . 2G12 binding, which has a known tolerance for Man 9 GlcNAc 2 glycans, was mostly unchanged upon ki- funensine treatment (Fig. 4C) , consistent with previous observations (34) . In contrast, PGT135 binding was dramatically reduced compared to that of the wild type. Our site-specific glycosylation analysis showed that 16% of the glycans at the Asn392 site of recombinant gp120 BaL were Man 9 GlcNAc 2 , which corresponds well with the observed maximal neutralization of BaL pseudovirus (Fig. 4A) . In contrast the magnitude of the plateau is not consistent with the much larger population of Man 9 GlcNAc 2 glycans (almost 50%) observed at the N332 site. This constraint, excluding Man 9 GlcNAc 2 at the Asn392 site, is further supported by the significant decrease in neutralization observed upon kifunensine treatment (15) . In contrast, modeling of a Man 9 GlcNAc 2 glycan at the Asn332 site suggested that a D2 terminal mannose could be accommodated with a minor conformational change, and thus FIG 2 Glycans present at the Asn332 glycosylation site. Recombinant, monomeric gp120 BaL was expressed in HEK 293T cells from the pHLsec vector (41) and purified by metal-affinity and size exclusion chromatography, as previously described (42) . gp120 was reduced, alkylated, and digested with trypsin (Promega), before fractionation using a Jupiter C 18 5-m 250-by 4.5-mm column (300-Å pore size) and a Dionex U3000 liquid chromatography system. Fractions were collected every minute, at a flow rate of 1 ml/min, for 90 min, and then analyzed on an Autoflex Speed . Y-type fragmentation of glycosidic bonds was also observed. (C) HILIC-UPLC profile of Asn332 glycans. Glycans were released from the QAHCNLSR glycopeptides by in-solution PNGase F (QA-Bio) digestion, according to the manufacturer's instructions, and then labeled using a LudgerTag 2-AB labeling kit (Ludger Ltd., Abingdon, United Kingdom). Chromatography was performed on a Waters Acquity UPLC instrument. Glycans were assigned by comparison with known oligomannose-type glycan standards (Ludger Ltd., Abingdon, United Kingdom).
the microheterogeneity observed at this site is likely to be better tolerated. Similarly, we note that PGT128 could achieve almost complete neutralization despite the observed microheterogeneity at the Asn332 site (Fig. 4A) . Incompatible glycoforms at the secondary binding site, N301, could account for the incomplete neutralization. The interaction between PGT135 and the glycan at Asn386 was observed to make a much smaller contribution to binding (15) , suggesting that an imperfect glycan match would not be as detrimental to binding. Indeed, removal of the Asn392 glycan site completely abolished neutralization by PGT135, whereas a degree of neutralization was retained upon removal of the N386 glycan site, with the neutralization plateau reduced to approximately 30% (Fig. 4A) . Removal of Asn137, which has been shown to enhance neutralization of some viruses by other N332-directed antibodies (35, 36) , had no effect on PGT135 or PGT128 neutralization. Similarly the N295 glycan, which has been observed to be important in a strain-dependent manner (15), had no effect on PGT135 binding. In contrast to PGT135 and PGT128, b12 neutralization of wild-type virus reached 100%. However, neutralization potency was increased by removal of the Asn386 glycan (Fig. 4A) . This phenomenon has been previously reported and is thought to arise from improved accessibility to the b12 epitope at the CD4 binding site following removal of this proximal glycan (37, 38) . Thus, Env glycans can influence neutralization by both glycan-directed and protein-directed bnAbs via distinct mechanisms.
Neutralization plateaus below 100% have previously been observed with glycan-reactive bnAbs (1, 3, 15, 22, 39) . The corresponding resistant populations could arise from either incomplete occupancy or the presence of unfavorable glycan structures at target glycosylation sites. A recent study suggested that most sites were 100% occupied (33) , while other work has suggested occupancy may be incomplete for some sites (32). We did not detect unglycosylated peptides at the N392 site (data not shown) but cannot formally exclude the possibility of such a small population existing below our detection limits. While nonoccupancy of a target glycosylation site may offer one mechanism of neutralization resistance, the ability of glycosylation inhibitors such as kifunensine or swainsonine to modulate the plateau of neutralization strongly suggests that the presence of tolerable glycoforms is an ϩ , and potassium, [M ϩ 39] ϩ , adducts were observed: both peaks were used for measuring abundances (Table 1) . (B) MALDI MS/MS fragmentation spectrum of the peak corresponding to the Man 8 GlcNAc 2 glycopeptide. Fragmentation peaks corresponded to the protonated masses. (C) MALDI MS of Asn386 glycopeptides (YCNSTQLF). The cysteine was modified due to treatment with iodoacetamide (carbamidomethyl, ϩ57). Protonated glycopeptides, as well as sodium and potassium adducts, were detected: all were used for calculation of abundances (Table  1) . (D) MALDI MS/MS fragmentation spectrum of the peak corresponding to the Man 8 GlcNAc 2 glycopeptide. Fragmentation peaks corresponded to the protonated masses.
important parameter for the efficacy of glycan-reactive bnAbs. This is an important consideration for vaccine design, since any elicited bnAb response will likely require a degree of plasticity in glycan recognition in order to counteract the intrinsic microheterogeneity of gp120 glycosylation. The precise degree of microheterogeneity will likely differ between isolates, as the various distributions of glycan sites may alter the local accessibility of processing enzymes. While this could be considered a potential barrier to targeting the HIV-1 glycan shield for vaccine purposes, recent investigations into the specificity of glycan-reactive bnAbs have suggested that they possess considerable plasticity in their mode of recognition. This has been demonstrated in particular for the Asn332-targeted antibodies, many of which can still neutralize diverse viruses when the Asn332 glycan is shifted or completely removed (30) . Thus, while greater insight is needed into the microheterogeneity of key antibody epitopes and the flexibility of bnAb recognition, the elicitation of glycan-targeting bnAbs remains a promising strategy for vaccine design.
